TROG Cancer Research
Members Login   CQMS Login

TROG 08.03 (RAVES)


Title: Radiotherapy - Adjuvant Versus Early Salvage. A Phase III Multi-centre Randomised Trial Comparing Adjuvant Radiotherapy (RT) With Early Salvage RT in Patients With Positive Margins or Extraprostatic Disease Following Radical Prostatectomy.

Primary sponsor: Trans Tasman Radiation Oncology Group (TROG)
Collaborating groups: Urological Society of Australia & New Zealand (USANZ); Australian & New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Psycho-Oncology Co-operative Research Group (PoCoG)

Final Accrual: 333

Expected closed to follow-up date: December 2021

Trial chair/s:
Dr Maria Pearse, Auckland Hospital, NZ

Trial contact:
Ms Carol Fraser-Browne
Auckland Regional Cancer and Blood Service, Private Bag 92024, Auckland, New Zealand 1142
Phone: +64 9 307 4949 ext 25197

Clinical trial registration:
ANZCTR: NCT00860652 NCT00860652

Trial documentation

Case Reports Forms
Certificate of Currency
SAE Form

Quality Assurance

In the RAVES trial, the quality assurance programme will allow us to confirm that participants have understood the technical guidelines within the protocol and implemented them correctly and that the dose prescription is delivered with appropriate documentation.

The programme consists of two parts:

  1. Each clinician that will be entering patients into the trial will be required to participate in a dry run contouring exercise before recruiting the first patient (credentialing).

  2. For all registered patients, treatment planning data will be submitted in electronic format.

The following documents can be used to assist in completing both parts of the Quality Assurance Programme

Summary for Radiation Therapists
Section 8 of the RAVES Protocol
Guidelines for Contouring
IMRT Credentialing Requirements

The data from the quality assurance programme will be analysed separately from the main trial. You will be notified of any major discrepancies


Facility Questionnaire
Benchmarking Instructions
Benchmarking CT Data Set - Patient A
Benchmarking Data Submission Form

Patient Case Review

QA Checklist - Eligibility
QA Checklist - RT Planning
QA Checklist - RT Treatment

Interim results

Please refer to the TROG Publications page 

Sundaresan P, Turner S, Kneebone A, Pearse M, Butow P. Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiother Oncol. 2011; 101 (3): 521-524.

Pearse M, Fraser-Browne CL, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim T, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the RAVES trial (Radiotherapy – Adjuvant Versus Early Salvage).  British Journal of Urology International.  2014; 113 (S2): 7-12.

Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH.  Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early Lessons from the 08.03 RAVES Trial. Clinical Oncology.  2014; 26(6): 348-352.


  • Sproston C, Willis D, Thompson A, Kneebone A, Pearse M, Wiltshire K, Haworth A. Rants on RAVES (Radiotherapy Adjuvant Versus Early Salvage): The challenge to meet dose constraints. J Medical Imaging and Radiation Oncology Vol 53, Supplement 1, Oral abstracts O22 – Scientific Paper/oral. RANZCR/AIR/FRO/ACPSEM Combined Scientific Meeting, October 2009.
  • Haworth A, Wiltshire KL, Kneebone A, Sproston C, Willis AD, Thompson A, Sidhom M, Tang C, Williams S and Pearse M. Importance of bench marking exercises in new trial protocols – the TROG 08.03 experience. European Society for Therapeutic Radiology and Oncology (ESTRO) Annual Scientific meeting. Barcelona September 2010.
  • Woo H. TROG 08.03: RAVES (Radiotherapy Adjuvant Versus Early Salvage). 12th Australasian Prostate Cancer Conference, Melbourne August 2011.
  • Pearse M, Kneebone A, Duchesne G, Fisher R, Fraser-Browne C, Frydenberg M, Haworth A, Jose C, Joseph J, Lim T, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Williams S, Wiltshire K, Woo H, Davis I. What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The "RAVES" phase III randomized clinical trial. J Clin Oncol. 2012; 30 (15 suppl): TPS4690.


RAVES DA (TROG 0803 substudy)

Become a TROG member and join our community of over 1,000 health professionals.

Latest News

  • 12 Feb 2019

    a new clinical trial by trog cancer research has shown for the first time that a new radiotherapy technique produced greater survival rates in early stage inoperable lung cancer patients, compared to conventional radiation treatment. the trog 09.02 chisel study aimed to investigate if...

  • 29 Jan 2019

    results from australia’s and new zealand’s biggest cancer trial have identified the best treatment regime for men suffering from newly-diagnosed aggressive but localised prostate cancer. the radar study, run through trog cancer research, compared the use of hormone treatment (longer v...

  • 07 Aug 2018

    trog cancer research has been successful in being awarded a $1.5 million grant (2018-2020) under the cancer australia support for cancer clinical trials program. the funding from cancer australia provides essential infrastructure for trog to build our capacity to undertake cancer...

  • 07 Aug 2018

    the board of trog cancer research is pleased to announce the appointment of susan goode as the new trog chief executive officer. susan is formerly the centre manager for the hunter cancer research alliance at the university of newcastle. in this role, she was key player in a strate...